66016-28-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Phenylcyclobutanecarboxylic acid is used as an intermediate in the synthesis of various pharmaceutical compounds for its unique structural features that can be leveraged to create new drugs with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Phenylcyclobutanecarboxylic acid serves as a key building block for the creation of complex organic molecules, potentially leading to advancements in material science and the development of novel chemical entities.
Used in Research and Development:
3-Phenylcyclobutanecarboxylic acid is utilized in research settings to explore its biological activities and potential interactions with biological systems, which may contribute to the discovery of new therapeutic agents or a deeper understanding of biochemical processes.

InChI:InChI=1/C11H12O2/c12-11(13)10-6-9(7-10)8-4-2-1-3-5-8/h1-5,9-10H,6-7H2,(H,12,13)

Upstream product

• 1570-97-4 3-phenylcyclobutane-1,1-dicarboxylic acid 
• 227935-29-7 methyl 3-phenylcyclobutane-1-carboxylate 
• 23761-26-4 3-phenyl-3-hydroxycyclobutane-1-carboxylic acid 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 108-86-1 bromobenzene 

Downstream Products

• 62485-19-2 cis-methyl 3-phenylcyclobutane-1-carboxylate 
• 62485-20-5 trans-methyl 3-phenylcyclobutane-1-carboxylate 
• 69584-46-9 3-phenylcyclobutane-1-carbonyl chloride 
• 69584-48-1 1-(hydroxymethyl)-3-phenylcyclobutane 
• 227935-29-7 methyl 3-phenylcyclobutane-1-carboxylate 
• 69584-36-7 3-Cyclohexyl-cyclobutanecarboxylic acid 
• 1570-98-5 Phenyl-3 cyclobutanique 

Relevant academic research and scientific papers

ANTIDIABETIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

New prolyl endopeptidase inhibitors: In vitro and in vivo activities of azabicyclo[2.2.2]octane, azabicyclo[2.2.1]heptane, and perhydroindole derivatives

A series of potent and selective prolylendopeptidase (PEP) inhibitors of the α-keto heterocyclic type has been obtained by replacing the classical central proline of 1-[1-(4-phenylbutanoyl)-L-prolyl]pyrrolidine (SUAM 1221, 3) by non-natural amino acids PHI, ABO, and ABH. These 4-phenylbutanoyl side- chain-containing inhibitors exhibited potent in vitro inhibitory potencies with IC50 around 30 nM (compounds 24 and 25). Modulation of the side chain by replacement of the terminal phenyl ring by the dicyclopropyl moiety afforded derivatives 30 and 32 with improved potencies (IC50 between 10 and 20 nM). Furthermore, replacing the linear 4-phenylbutanoyl side chain by the (2-phenylcyclopropyl)carbonyl entity provided potent inhibitors with IC50 culminating at 0.9 nM on a rat cortex enzymatic preparation (compound 70). The configuration of the cyclopropyl ring had to be R,R in order to obtain not only a strong PEP inhibition in vitro but also a good activity in vivo, exemplified by inhibitor 68, which gave ID50 ip and po of 0.3 and 1 mg/kg, respectively. Finally, demonstration of the cognition-enhancing properties of compound 54 was given in the passive avoidance test using scopolamine- induced amnesia in the rat, where it dose dependently inhibited the scopolamine-induced decrease in avoidance response.

Vibrational Spectrum, Structure, and Energy of Propellane

The structure of propellane (bond lenghts and angles) was determined from an analysis of the rotational components of the infrared bands of the parent compound and of its d6 derivative, and it was found to be in good agreement with the structure ca